ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen patients’ natural immune system to fight cancer.
Culver City, CA
- Tweets 943
- Following 130
- Followers 19,954
- Likes 609
We’ve announced that our initial data shows 100% disease control in 5 out of 5 patients with recurrent glioblastoma after being treated with our ANKTIVA, NK cell therapy plus the Optune Gio® device. Read more: immunitybio.com/initial-data…
94
369
38,013
Thrilled about the news that our partners Drs. Hotez and Bottazzi have been nominated for the Nobel Prize for their work on low-cost #COVID-19 vaccine that’s already in use in India. Congratulations on the well-deserved recognition! @TexasChildrens @PeterHotez @mebottazzi
3
29
223
The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow, Dr. Fred Ramsdell, and Dr. Shimon Sakaguchi, recipients of the 2025 Nobel Prize in Physiology or Medicine.
This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance, providing the foundation for developing novel therapies targeting cancer and infectious diseases.
We recognize and applaud their contributions to immunology, which continue to inspire innovation. Read more: nobelprize.org/prizes/medici…
9
38
252
7,651
We've announced our new study, called COVID-4.019-Long, which further expands our clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: ir.immunitybio.com/news-rele…
26
51
246
19,059
We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: immunitybio.com/immunitybio-…
21
57
227
96,446
We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield™ platform, anchored by ANKTIVA®, to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy. Learn more: immunitybio.com/immunitybio-…
23
51
217
9,914
We’ve announced new paradigm-changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), with this reversal resulting in significant prolonged median overall survival (mOS). Read more: immunitybio.com/immunitybios…
5
53
218
13,295
At ImmunityBio, we're redefining cancer care. Our mission focuses on developing treatments that are not only effective, but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment, offering hope through innovative therapies. Learn more about our vision: immunitybio.com/founders-vis…
5
31
162
5,571
Today, we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent, ANKTIVA® (nogapendekin alfa inbakicept-pmln), in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. Learn more: immunitybio.com/uk-mhra-appr…
37
166
9,824
Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system, facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: immunitybio.com/pipeline/
10
36
156
4,583
We’ve reported a 60% revenue increase in Q2 2025, with year-to-date sales reaching $43M and a 246% growth in ANKTIVA® sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: immunitybio.com/immunitybio-…
38
25
162
7,143
Dr. Patrick Soon-Shiong presented groundbreaking insights on harnessing NK cells and memory T cells to fight urological cancers today at the #AUA2025 Innovation Nexus. We’re honored to collaborate with healthcare professionals in advancing treatments for bladder cancer.
22
149
3,965
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it. View our pipeline: immunitybio.com/pipeline/
13
22
155
6,126
We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield™ platform to Saudi Arabia and the broader Middle East. Learn more: immunitybio.com/immunitybio-…
15
26
145
10,439
Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness.
We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery.
11
31
142
5,718
This weekend's BCAN Patient Summit in Columbus brought together patients, caregivers, and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission.
11
28
148
9,541
We reported another quarter of strong results, driven by increased demand for ANKTIVA® and continued progress across our immunotherapy pipeline. In Q3 2025, we achieved significant year-to-date unit growth of 467% and $75 million in total product sales, reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer.
As we close out the year, we remain committed to expanding access to our therapies, advancing ongoing trials across multiple indications, and executing our long-term vision to transform how cancer is treated.
Read the full release, including important cautionary statements about forward-looking information: immunitybio.com/driven-by-st…
11
26
153
5,883
We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people, deep scientific knowledge, and advanced research and manufacturing facilities, ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: immunitybio.com/founders-vis…
12
26
140
4,706
Annually, over 230,000 people in the United States are diagnosed with lung cancer, with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells, empowering the immune system to better combat NSCLC. Learn more about our approach: immunitybio.com/non-small-ce…
10
32
136
4,984
Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate, mission-driven individuals to grow with us.
Be a part of something bigger. Explore open positions and apply today: immunitybio.com/careers/
11
30
130
5,462
Yesterday’s investor meeting was an important moment to align with key opinion leaders and shareholders on our continued progress toward delivering better treatment options for patients.
18
130
3,422
We’re thrilled to announce today @US_FDA approved a first-in-class treatment for BCG-unresponsive non-muscle invasive bladder cancer #NMIBC. Learn more: immunitybio.com/immunitybio-… $IBRX
14
31
124
8,562
At ImmunityBio, we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials, individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: immunitybio.com/find-a-trial…
3
25
122
6,825
Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA® for eligible veterans with BCG-unresponsive NMIBC. Read more: immunitybio.com/immunitybio-…
8
22
119
4,439
The FDA has granted ImmunityBio a Regenerative Medicine Advanced Therapy designation to evaluate whether ANKTIVA® and CAR-NK can reverse lymphopenia in patients undergoing standard-of-care chemotherapy for locally advanced or metastatic pancreatic cancer. Learn more about our innovative approach to addressing this unmet need in cancer: immunitybio.com/immunitybio-…
21
113
7,076
On this International Clinical Trials Day, we at ImmunityBio are dedicated to transforming the future of cancer treatment. This journey wouldn't be possible without the invaluable contributions of our clinical trial participants. Together, we are pioneering breakthroughs.
5
18
118
2,524
We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: immunitybio.com/pipeline/
4
25
116
3,685
Lymphopenia remains a critical challenge for patients undergoing cancer treatment, often compromising immune function and increasing the risk of complications. At ImmunityBio, we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: immunitybio.com/lymphopenia/
10
27
114
4,208
Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: immunitybio.com/pipeline/
12
29
114
3,267
Join us now at the product theater where Dr. Patrick Soon-Shiong is presenting our innovative approach to addressing the BCG shortage in bladder cancer. Learn how we’re advancing therapeutics for better patient outcomes.
15
104
3,650
According to the American Cancer Society, lung cancer accounts for nearly 1 in 5 cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: immunitybio.com/non-small-ce…
6
23
107
3,616
Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: immunitybio.com/bladder-canc…
5
23
101
4,058
"Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio, we're working to transform how cancer is treated by designing therapies that not only target disease, but restore the body's natural ability to fight it. View our pipeline: immunitybio.com/pipeline/
5
27
99
2,982
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio, we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: immunitybio.com/non-small-ce…
6
19
98
5,339
Today, we announced our first patient dosed in our recombinant BCG (rBCG) FDA-authorized Expanded Access Program. With 60 sites launching, providers like U.S. Urology Partners are helping address the nationwide BCG shortage. Learn more: immunitybio.com/immunitybio-…
12
15
101
4,475
Bladder cancer incidence is rising, but so are the options for patients facing this diagnosis. At ImmunityBio, we are working to improve outcomes and reduce the burden of treatment for patients with non-muscle invasive bladder cancer. As the need grows, so does our commitment to developing solutions designed to harness the body's own immune system.
7
23
98
3,278
At ImmunityBio, our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer, we are dedicated to making a meaningful impact. Join us in our journey to transform the future of healthcare by viewing our pipeline: immunitybio.com/pipeline/
1
18
98
3,134
Lynch syndrome affects an estimated 1 in 279 in the U.S., emphasizing the importance of awareness and early detection in order to prevent cancers like colon cancer. ImmunityBio’s investigational study aims to improve outcomes for those affected. Learn more: immunitybio.com/lynch-syndro…
3
23
96
2,809
ImmunityBio Chief Medical Officer Dr. Bobby Reddy presenting QUILT 2.005 (BCG naive) study in Clinical Trials in Progress session at #AUA24
6
17
93
3,624
We're pleased to announce we've completed GMP drug substance manufacturing sufficient for 170,000 doses of our newly approved treatment. Exciting times ahead! shorturl.at/MOW08
4
23
96
5,483
Advanced ovarian cancer presents significant challenges, especially for this with platinum-resistant recurrence. ImmunityBio is working on potential solutions through our clinical trial for recurrent platinum-resistant high-grade ovarian cancer. Our goal is to provide new hope where options are limited. Visit our website to learn more: immunitybio.com/ovarian-canc…
3
15
92
2,806
🚨 On the heels of the FDA approval of our combination therapy for treatment of #NMIBC, ImmunityBio and @seruminstindia have agreed to an exclusive arrangement for global supply of BCG. Read More: immunitybio.com/immunitybio-…
2
21
86
4,315
Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies, working every day to expand treatment options and improve outcomes for patients.
4
18
89
3,515
The FDA's green light for our first-in-class IL-15 receptor marks a new era in treating #NMIBC. In this interview with @UrologyTimes, @drpatrick sheds light on the pivotal approval. #IBRX #BladderCancer
bit.ly/4b9qg3c
6
22
86
4,732
On this Independence Day, we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday.
16
89
3,059
ImmunityBio’s latest QUILT 3.032 data demonstrates the longest duration of complete response and the highest rate of cystectomy avoidance within the non-muscle invasive bladder cancer space. Watch Dr. Sam Chang's oral presentation here: vimeo.com/1079187906?utm_sou… and explore the most recent data: immunitybio.com/unmatched-lo…
4
19
89
3,437
ImmunityBio’s state-of-the-art GMP biological manufacturing facility in Dunkirk, New York ir.immunitybio.com/news-rele…
6
16
85
2,689
This week's @US_FDA approval of a new treatment option for BCG-unresponsive non-muscle invasive bladder cancer has the potential to represent a new standard of care for patients. Learn more: bit.ly/3Jtp8vk #BladderCancer $IBRX
4
30
91
3,427
Thank you Howard Fine at @LABJnews for covering the many exciting happenings at ImmunityBio - including the progress and future of our newly FDA-approved #immunotherapy.🧪🔬 labusinessjournal.com/health…
5
21
84
3,741
In an interview today with @YahooFinance, ImmunityBio Chairman, @drpatrick , spoke with @AnjKhem about what the approval of #Anktiva means for ImmunityBio as well as investors. Check out their conversation here ⬇️ $IBRX
Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..."
4
22
92
11,676
ImmunityBio today announced that the FDA has authorized an Expanded Access Program (EAP) to improve U.S. patient access to BCG, a standard-of-care treatment for non-muscle invasive bladder cancer. Learn more: immunitybio.com/fda-authoriz…
5
18
84
25,307
ImmunityBio is honored to be recognized as one of @FastCompany's most innovative companies of 2025. Innovation is at the core of our mission as we work to develop cutting-edge therapies and create better outcomes for patients. We remain committed to transforming the future of medicine and delivering hope to those in need.
3
16
83
5,871
With high rates of recurrence and the risk of advancing disease, non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers.
ImmunityBio is working to meet this challenge through the development of innovative treatment approached aimed at addressing the disease more effectively. Learn more: immunitybio.com/bladder-canc…
3
19
81
4,690
Addressing the complexities of cancer and infectious diseases fuels our pursuit of new therapies that provide better outcomes for patients. If you're looking for a career with purpose, become a part of our innovative team: immunitybio.com/careers/
7
11
80
6,399
ImmunityBio is excited to showcase our latest advancements in bladder and prostate cancer at the American Urological Association Annual Meeting. Learn more about our keynote presentations: immunitybio.com/immunitybio-…
2
15
81
3,738
We position ourselves at the forefront of cancer research, striving to gain deeper insights and develop more effective treatments for patients. Learn more about our ongoing clinical trials: immunitybio.com/pipeline/
7
16
76
6,022
Every November, Lung Cancer Awareness Month shines a light on the importance of education, early detection, and innovation. ImmunityBio is proud to support this awareness by pursuing scientific advancements designed to improve outcomes for patients facing lung cancer. Learn more: immunitybio.com/non-small-ce…
7
10
80
2,867
ImmunityBio and @MSFTResearch donate a combined 24 petaflops of GPU computing power to create models for researchers working on #coronavirus vaccines & therapeutics. Models can be derived in days, rather than the months it would normally require. immunitybio.com/immunitybio-…
4
26
63
Bladder Health Month provides us with an opportunity to reflect on the progress made through science and the compassion that drives it forward. Behind every clinical advancement are patients, nurses, physicians, and caretakers determined to improve the future of bladder cancer care.
We share that mission - to transform how bladder cancer is treated and to restore the body's ability to fight disease. Together, with organizations like @BladderCancerUS and @UrologyCareFdn, we work toward a future defined by better outcomes and renewed hope.
15
78
5,258
ICYMI: Earlier today we announced the first NMIBC patients have been treated with commercially available doses of ANKTIVA, less than two months after we received FDA approval for this exciting new therapy.
immunitybio.com/immunitybio-…
8
12
66
2,984
Hope moves science forward.
This month, we honor the strength of the bladder cancer community and remain committed to transforming the treatment landscape through therapies that empower the immune system to fight cancer more effectively.
1
7
76
2,296
ImmunityBio announced the first patients dosed in our Phase I clinical study of CAR-NK therapy for the treatment of relapsed B-Cell non-Hodgkin’s lymphoma. Learn more: immunitybio.com/first-patien…
29
14
68
30,558
ImmunityBio is at the forefront of transforming bladder cancer treatment. Our innovative research aims to develop more effective therapies. Visit us to learn about our groundbreaking work and how we're making a difference: immunitybio.com/bladder-canc… #BladderCancer #ImmunityBio
4
14
64
2,988
“Until we have a second-generation vaccine that actually stops transmission, [the pandemic] will not be over” shared ImmunityBio Founder @drpatrick today on @QuestMeans. ImmunityBio is proud to begin phase 3 clinical trials for our COVID vaccine in Africa next week.
$IBRX
Botswana is getting big investment in a COVID vaccine center.
ImmunityBio Founder and Executive Chairman Patrick Soon-Shiong talks about his investment in the center and what increased access to vaccines would mean globally.
11
25
66
Lung cancer is the leading cause of cancer death in the US, killing 125,000 annually. Over 234,000 are diagnosed each year, most with non-small cell lung cancer. A form where more advances are needed, and we're working on better treatments. Learn more at ImmunityBio.com
7
10
63
3,140
ImmunityBio is pleased to announce positive results from our QUILT 3.055 trial, showing extended survival of 14 months to 5 years for lung cancer patients treated with checkpoint inhibitors. Read more: immunitybio.com/immunitybio-…
9
12
69
30,830
Latest data from the QUILT 88 trial shows Nant Cancer Vaccine more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer. Principal Investigator Dr. Tara Seery presented the poster at #ASCO22 Abstract #4147, poster #132
4
19
61
As Bladder Cancer Awareness Month concludes, our hearts remain with those affected. ImmunityBio is committed to advancing care and supporting patients every step of the way.
2
10
67
2,513
We are happy to share that, as a proud sponsor of the SITC event at Buddy Guy’s Legends, we helped raise over $60,000 through the Forward Fund. These funds will directly support the programs, awards, and grants that advance the professional development of investigators, ensuring a bright future for innovation in immunotherapy.
7
67
2,182
We are honored to have participated in BCAN Walks across the U.S., advocating for patient voices and supporting the incredible work of @BladderCancerUS. Thank you to everyone who joined us in raising awareness for those affected by bladder cancer.
12
66
2,771
Immunityio has partnered with BeiGene (soon to be BeOne Medicines) for a Phase 3 trial aimed at evaluating the efficacy and safety of two immunotherapeutic agents in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. Learn more about this effort to advance treatments for those facing unmet needs in oncology: immunitybio.com/immunitybio-…
7
13
67
3,695
A recent Harris survey found that a vast majority of patients with non-muscle invasive bladder cancer (NMIBC) see intravesical chemotherapy as a last resort, whereas 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects.
With patients at the forefront, ImmunityBio continues to focus on innovative approaches designed to preserve bladder function and improve quality of life for those facing difficult treatment decisions. Read more here: immunitybio.com/new-survey-r…
6
22
80
3,338
The Immunitybio team is excited to be part of the @AmerUrological's #AUA24 conference #ImmunityBio #BladderCancer
1
8
63
1,679
Recently, our founder @drpatrick spoke to @UrologyTimes about promising data presented at the @AmerUrological annual meeting, specifically highlighting our ongoing QUILT 2.005 study in BCG-naïve #NMIBC. Watch here: urologytimes.com/view/dr-soo…
1
15
66
2,926
Interested in hearing more about our newly approved bladder cancer immunotherapy? Check out new interviews with @drpatrick and Dr. Bobby Reddy on the @urotoday podcast series with @UroDocAsh, here: immunitybio.com/connecting-t…
1
17
62
2,602
ImmunityBio is dedicated to transforming the way we fight cancer and infectious diseases by empowering the body's own immune system. Our mission is to not only treat illness, but to provide lasting protection that gives patients hope for a healthier future. Learn more about our pipeline: immunitybio.com/pipeline/
3
8
64
3,546
ICYMI: AUA Daily News covered @drpatrick 's fireside chat with Dr. Sam Chang @UroCancerMD at #AUA2024
2
15
59
3,120
This National Urology Nurses Week, ImmunityBio recognizes the dedication and expertise of urology nurses who provide compassionate care to patients every day. Your commitment helps improve outcomes and quality of life for individuals navigating urologic conditions, including bladder cancer.
Thank you for all that you do.
4
11
68
2,783
ICYMI: @drpatrick participated in a fireside chat with Dr. Sam Chang at #AUA24: auadailynews.org/meeting-cov…
1
10
60
2,300
ICYMI: ImmunityBio management recently provided an update on registration plans for #NSCLC, status of #ANKTIVA launch readiness for #NMIBC, and ANKTIVA as the backbone of company’s clinical trial pipeline for multiple tumor types. Learn more: immunitybio.com/investor-liv…
1
14
62
3,011
Many individuals with Lynch syndrome are unaware that they carry the gene mutation until they're diagnosed with cancer, making education, early detection, and clinical research critically important. Our clinical trial is designed to explore potential treatment options for those with Lynch syndrome. Learn more: immunitybio.com/lynch-syndro…
5
16
64
6,353
Tomorrow, we are participating in the @WhiteHouse summit on next-generation #COVID vaccines. Our vaccine candidates are designed to thwart future coronavirus variants and provide longer duration protection. Tune in here: bit.ly/3J2yYmT. @WHCOVIDResponse
7
15
56
At ImmunityBio we are revolutionizing cancer and infectious disease treatments with a powerful new approach. Our therapies are designed to do more than today's treatments by boosting the body's own immune response for long-term protection. #NextGenImmunotherapy #ImmunityBio
2
8
59
1,902
We're working toward a future where patients not only live longer, but live better - with more meaningful time spent doing what matters most.
3
11
60
2,604
Field Medical Director, Dr. Rachel Elward, reflects on the unique fulfillment of working in immunotherapy, driven by the potential to transform patient lives. Learn more about our approach: immunitybio.com/patients/
3
7
61
6,219
Bladder cancer can often go undetected until it has progressed. Early diagnosis and access to new treatment options are critical to improving outcomes for those affected. Learn more about how we're committed to advancing research and exploring new possibilities through our clinical trials: immunitybio.com/bladder-canc…
8
7
54
6,131
Our unwavering commitment to advancing patient care drives us to explore new frontiers. We're dedicated to transforming lives through innovative therapies where they matter most. See our pipeline: immunitybio.com/pipeline/
10
60
2,027
This Veterans Day, we reflect on the sacrifices made by those who served our country and the importance of improving health outcomes for veterans living with cancer and other serious diseases. Their resilience drives our ongoing pursuit of better care for all patients.
Thank you.
2
9
63
2,112
ImmunityBio is working towards a future free from fear of cancer. By tapping into the power of the immune system, we're innovating therapies that bring new hope to patients and their loved ones. View our pipeline: immunitybio.com/pipeline/
11
11
57
2,220
We're focused on driving innovation in bladder cancer care - starting where it's most commonly diagnosed: non-muscle invasive disease. At ImmunityBio, advancing treatment options remains a critical priority. Learn more: immunitybio.com/bladder-canc…
3
14
58
2,324
During Bladder Cancer Awareness Month, we at ImmunityBio reflect on our mission to innovate and improve the lives of those battling this disease. Our relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients. Learn more by visiting immunitybio.com/bladder-canc….
4
10
60
3,762
We're pleased to share the FDA has accepted for review our BLA for N-803+BCG for BCG-unresponsive NMIBC. With this important step, we're closer to being able to offer a promising combo therapeutic to people living w/ #NMIBC and, ultimately, reducing the incidence of cystectomies.
3
8
48
September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment.
This month, and every month, we're dedicated to supporting patients and driving research forward. Learn more about our trial: immunitybio.com/ovarian-canc…
2
6
57
3,109
We're honored to be partnering with #IDRI & Texas Children's Hospital Center for Vaccine Development on 2nd gen COVID-19 vaccines #COVID19 $IBRX
axios.com/the-new-covid-vacc…
6
11
53
Our dedication fuels breakthrough innovations, aiming to improve outcomes for all patients. Learn more about our founder's vision: immunitybio.com/founders-vis…
3
9
56
2,407
We’re live with @drpatrick and @UroCancerMD discussing the potential of Anktiva in battling #BladderCancer. #AUA24 #ImmunityBio
11
53
2,800
In an interview with @TeamCavuto on @FoxBusiness, ImmunityBio founder, @drpatrick, highlighted the unique mechanism of action for Anktiva and reiterated our belief in Anktiva and its potential efficacy as a next-generation immunotherapy across multiple tumor types. $IBRX
12
63
2,768
Bladder Cancer Awareness Month is a time to reflect on the impact of this disease and the advancements being made. At ImmunityBio, we're committed to developing treatment options that improve outcomes for those affected. Together, we're working toward a future with more effective and accessible therapies.
11
54
1,757
We’re looking forward to meeting with healthcare providers at the Large Urology Group Practice Association (LUGPA) regional meeting this week in Las Vegas and sharing ideas and advancing our understanding of treating bladder cancer.
lugpa.org/vegas-regional-202…
4
6
52
2,019
Did you know that certain occupations carry a higher risk of bladder cancer due to exposure to harmful chemicals? An estimated 10% of all bladder cancer cases are considered ‘occupational’, meaning they can be attributed to exposure to cancer-causing agents at work. Learn more about how we're advancing bladder cancer treatment and support for those affected: immunitybio.com/bladder-canc…
1
10
54
2,265